Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02439645
Other study ID # 2013P001531
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date October 2013
Est. completion date July 26, 2019

Study information

Verified date November 2021
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is a registry to examine genetic and clinical predictors of torsade de pointes events.


Description:

BACKGROUND AND SIGNIFICANCE Drug-induced long QT syndrome (LQTS), and the subsequent fatal arrhythmia torsade de pointes (TdP), is an important side effect associated with the use of a number of medications. Prolongation of the QT interval is the most common cause of withdrawal of medications already on the market, and despite the relatively rarity with non-cardiovascular drugs, the public health impact is magnified by the fact that drug-induced TdP can occur with medications used for benign conditions, such as allergic rhinitis. The QT interval is heritable, and a number of common genetic variants have been associated with QT interval in large population studies. Although common genetic variants associated with sudden cardiac death have been identified, studies specifically identifying variants associated with drug-induced LQTS and TdP are limited. Smaller studies have suggested that variants of genes associated with QT interval duration in the population in general are also associated with the risk of drug-induced QT prolongation and TdP, but larger studies are needed. Moreover, an improved ability to predict the causes of TdP requires a careful search for clinical factors associated with TdP compared to controls. RESEARCH DESIGN AND METHODS A. Study Design and Enrollment: We propose to conduct a multi-center research study to examine known and explore potentially unknown genetic and clinical predictors of torsade de pointes (TdP) also known as acquired long QT syndrome (LQTS) through creation of a registry. Any patient with a documented history of a torsade de pointes (TdP) event will be eligible. Patients must be able to understand the risks of genetic testing, and be willing to undergo a venipuncture for blood collection for genotyping. Exclusion criteria include inability to provide informed consent. We plan to enroll a total of 200 study participants total across all participating centers. Massachusetts General Hospital will be the coordinating center of this multi-center study of medical institutions within the greater Boston and New England area. In a substudy to take place at MGH, subjects will be invited to have a punch biopsy of the skin to allow creation of inducible pluripotent stem cells that can be differentiated into cardiomyocytes for further characterization of the repolarization phenotype. B. Study Procedures: We will screen patients for enrollment including both retrospective (event prior to the start of the study) and prospective (event following the start of the study) components. Patients will be identified by investigators based on clinical characteristics, and following explanation of the study by co-investigators, will be asked about participation either during routine scheduled follow-up (for retrospective cases) or at the sentinel event. Investigators will complete a data collection form for each patient, which will include contact information, demographic information, clinical information, family history and pedigree, and all electrocardiography information available (12-lead ECGs, rhythm strips and summary reports). No information about mental illness will be collected. Patients will then undergo venipuncture, and four 5mL blood samples will be collected for genotyping and plasma analysis. For patients who are willing, a 3mm punch biopsy from the shoulder, upper thigh, small of the back, or buttock (subject's choice) will be obtained for fibroblast culture. Patients who are recruited at non-MGH sites will have a visit to MGH scheduled in order to obtain the skin biopsy. Induced pluripotent stem cells will be made from the fibroblast cultures and differentiated to cardiomyocytes in order to assess the cellular phenotype. Patients will also be consented for future re-contact about additional data, information, or samples needed for analysis. All clinical information and samples (including DNA and blood) collected at participating centers will be transferred to Dr. Newton-Cheh at MGH for storage and analysis.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date July 26, 2019
Est. primary completion date July 26, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility For simplicity, we will plan to include all possible cases of TdP meeting criteria (see below) into the registry. Exclusion criteria include: 1. age <18 years old 2. inability to obtain informed consent from the patient or a family member 3. no exclusion on the basis of race or gender. Inclusion criteria include: torsade de pointes clinical syndrome according to one of the following three clinical criteria: 1. Definite TdP: At least 3 beats of polymorphic ventricular tachycardia (VT) or ventricular fibrillation (VF) on a 12-lead ECG or rhythm strip with documented QTc > 450 ms in men or QTc > 470 in women (excluding patients with conduction block or AF at baseline, see below) prior to arrhythmic event. 2. Probable TdP: At least 3 beats of polymorphic VT or VF on a 12-lead ECG or rhythm strip with QTc > 450ms (men) or 470ms (women) after the event, or polymorphic VT or VF episode not meeting criteria for 'definite TdP' but determined by the adjudicating physician to be likely TdP. For patients having a cardiac arrest, at least 1 hour after restoration of normal rhythm or after secondary hypoxia or electrolyte abnormalities have been ruled out (confounders of QT prolongation often seen post-arrest47) will be required. 3. Possible TdP: Unexplained syncope in a patient presenting with QTc > 450ms (men) or 470ms (women).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Boston University Medical Center Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States West Roxbury VA Medical Center West Roxbury Massachusetts

Sponsors (7)

Lead Sponsor Collaborator
Massachusetts General Hospital Beth Israel Deaconess Medical Center, Boston University, Brigham and Women's Hospital, Mayo Clinic, The Cleveland Clinic, US Department of Veterans Affairs

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Torsade de pointes arrhythmia events Definite TdP: At least 3 beats of polymorphic ventricular tachycardia (VT) or ventricular fibrillation (VF) on a 12-lead ECG or rhythm strip with documented QTc > 450 ms in men or QTc > 470 in women (excluding patients with conduction block or AF at baseline, see below) prior to arrhythmic event.
Probable TdP: At least 3 beats of polymorphic VT or VF on a 12-lead ECG or rhythm strip with QTc > 450ms (men) or 470ms (women) after the event, or polymorphic VT or VF episode not meeting criteria for 'definite TdP' but determined by the adjudicating physician to be likely TdP. For patients having a cardiac arrest, at least 1 hour after restoration of normal rhythm or after secondary hypoxia or electrolyte abnormalities have been ruled out (confounders of QT prolongation often seen post-arrest47) will be required.
Possible TdP: Unexplained syncope in a patient presenting with QTc > 450ms (men) or 470ms (women).
Participants will be followed for the time to obtain consent, clinical information and biospecimens (typically < 1 day)
See also
  Status Clinical Trial Phase
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4
Completed NCT01648205 - Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients Phase 2
Recruiting NCT06087367 - Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects
Recruiting NCT04675788 - Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening Phase 4
Completed NCT05759962 - Phase 1 Study of LQT-1213 in Healthy Adults Phase 1
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Recruiting NCT00221832 - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases N/A
Completed NCT04706104 - QT Measurement Techniques and Anesthesia Management
Recruiting NCT04336644 - Continuous Versus Intermittent cARdiac Electrical moNitorinG N/A
Recruiting NCT02814981 - Hydroxyzine and Risk of Prolongation of QT Interval N/A
Completed NCT02425189 - The Canadian National Long QT Syndrome Registry
Completed NCT02876380 - Prospective Identification of Long QT Syndrome in Fetal Life
Completed NCT00399412 - ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients N/A
Completed NCT02513940 - Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes Phase 4
Completed NCT02441829 - Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function Phase 1
Completed NCT03182777 - Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies N/A
Completed NCT01849003 - Study of the Effect of GS-6615 in Subjects With LQT-3 Phase 1
Completed NCT00316459 - Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects Phase 1
Completed NCT00292032 - Registry of Unexplained Cardiac Arrest
Recruiting NCT05348564 - Comparing Direct vs Indirect Methods for Cascade Screening N/A